Allen C. Bowling, M.D., Ph.D.


Neurology Care

701 E. Hampden Ave., Ste. 518
Englewood, CO 80113
phone 303-788-7667
fax 303-409-6800


1982   B.S.      Yale College, Summa Cum Laude, Phi Beta Kappa
1988   M.D.     Yale University School of Medicine
1988   Ph.D.    Dept. of Pharmacology, Yale University School of Medicine

Postdoctoral Training:

1988-1989       Internship, Internal Medicine Department, University of California – San Francisco
1989-1992       Residency, Neurology Department, University of California – San Francisco
1992-1995       Fellowship, Neurology Service, Massachusetts General Hospital and Harvard Medical School

Academic Positions:

1996-present    University of Colorado, Neurology Dept, Aurora, CO
1996-1997       -Clinical Instructor
1997-2003       -Assistant Clinical Professor
2003-2012       -Associate Clinical Professor
2012-present    -Clinical Professor

Foundation Positions:

1997-2008       Rocky Mountain MS Center, Englewood, CO
1997-2008       -Director, Complementary and Alternative Medicine Program
1997-2002       -Associate Medical Director
2003-2007       -Medical Director
2009-present    Colorado Neurological Institute (CNI)
2009-2014       -Medical Director, Multiple Sclerosis Program
2009-2014       -Medical Director, Complementary and Alternative Medicine Service
2014-present    -Chair of Education
2014-present    -Medical Advisory Committee
2014-present    -Physician Associate

Journal Position:

2006-2013       Editorial Board: Multiple Sclerosis Journal (formerly Multiple Sclerosis), Sage Publications

Committees and Advisory Boards:

2007-2014        Member, Quality Standards Subcommittee of the American Academy of Neurology (AAN)
2009-2013       Advisor, Guthy-Jackson Charitable Foundation, San Diego, CA
2001-present    Member, Healthcare Advisory Council, MS Association of America (MSAA)
2005-present    Ad Hoc Grant Reviewer, National MS Society (NMSS)
2007-present    Member, Committee for the Strauss-Wisneski Indigenous and Integrative Medicine Collection, University of Colorado
2012-present    Grant Reviewer, Patient Management, Care, and Rehabilitation Pilot Review Committee, National MS Society (NMSS)
2012-present    Member, Clinical Advisory Committee, Colorado-Wyoming Chapter of the National MS Society (NMSS)

Clinical Practice:

1995-1997       Western Neurological Group, Denver, CO
1997-2007       Colorado Neurology, Englewood, CO
2007-present   Neurology Care, address above

Licensure and Certification:

1993-present    Board Certification, American Board of Psychiatry and Neurology
1995-present    Medical License, Colorado Board of Medical Examiners

Awards and Honors:

2016            Neuroscientist of the Year Award, awarded by Colorado Neurological Institute for groundbreaking visionary work in clinical care, research, and writing
2011            “Top 10 MS Books,” Complementary and Alternative Medicine and Multiple Sclerosis chosen by the Consortium of MS Centers (CMSC) as one of the top 10 lay books on MS
2000            Award for Best Presentation in Patient Education, annual meeting of the Consortium of Multiple Sclerosis Centers
1999            Labe Scheinberg Award, annual meeting of the Consortium of Multiple Sclerosis Centers
1988            American Epilepsy Society Award
1988            Medical Scientist Training Program Student
1987            Saul R. Korey Award in Experimental Neurology (American Academy of Neurology)
1982            Summa Cum Laude, Yale College
1982            Phi Beta Kappa, Yale College
1982            Fellows’ Prize, Yale College
1982            Distinction in Major, Yale College
1982            Scholar of the House, Yale College
1981            Bates’ Summer Travelling Fellowship, Yale College


Click here for the “Lectures” page


Click here for the “Books” page


Click here for the “Articles” page

Clinical Studies

  1. April 2016 – Present

    An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-modifying Treatment
    Principal Investigator

  2. December 2015 – Present

    A Prospective Observational Registry of H.P. Acthar Gel for the Treatment of Multiple Sclerosis Relapse.
    Principal Investigator

  3. June 2014 – Present

    A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teiflunomide Treatment using Patient-Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
    Principal Investigator

  4. March 2013 – Present

    A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients with Secondary Progressive Multiple Sclerosis
    Principal Investigator

  5. October 2015 – June 2016

    A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-Over Study Evaluating Subject Ease-of-Use with Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) Treated with Rebif® 44mcg Subcutaneously Three Times a Week
    Principal Investigator

  6. December 2014 – November 2015

    Plegridy™ (peginterferon β-1a) Real World Effectiveness and Safety Observational Program
    Principal Investigator

  7. August 2014 – March 2016

    Botox® Treatment in Adult Patients with Upper Limb Spasticity

  8. September 2013 – February 2016

    A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (dimethyl fumarate) Delayed-Release Capsules in Patients with Relapsing Forms of Multiple Sclerosis after Suboptimal response to Glatiramer Acetate
    Principal Investigator

  9. Teva Neuroscience, Protocol PM 028: A Randomized, Controlled, Open-Label Parallel Group Study to Evaluate the Effect of Regularly Scheduled Neutralizing Antibody Testing on Treatment Patterns vs Usual Care in High Dose Interferon-Treated Subjects, 2007-2010.
    Principal Investigator

  10. Teva Neuroscience, Protocol PM 024: Partnership Study: A Study of Adherence to Immunomodulating Agents with MS Center Support Services, 2006-2008.

  11. Investigator-Initiated: Dietary Supplement Use Among People with Multiple Sclerosis, 2006-2009.

  12. Investigator-Initiated: Injection Site Reactions Produced by the Immunomodulating Agents (IMAs) Used in the Treatment of Multiple Sclerosis, 2004-2007.

  13. National MS Society, Project #9278: Comprehensive Evaluation of Multiple Sclerosis Adult Day Programs, 2005-2007.

  14. Investigator-initiated: A Survey of Issues Related to Prayer and Spirituality Among a Large Group of People with MS, 2005-2007.

  15. Investigator-Initiated: MS Patients and Marijuana Use Survey, 2004-2007.

  16. Investigator-Initiated: Rocky Mountain MS Center Internet-Based Disease Registry and Database, 2003-2009.

  17. Investigator-Initiated, National MS Society-supported: Rocky Mountain Multiple Sclerosis Center Tissue Bank, 2003-2009.

  18. Investigator-Initiated: Survey Of Issues Related To Cognitive Dysfunction Among A Large Group Of People With Multiple Sclerosis, 2004-2006.

  19. Teva Neuroscience, Protocol PM 07: A Multicenter, Randomized, Double-Blind Comparison of 3 Bevel versus 5 Bevel Needles, 2003-2005.

  20. Teva Neuroscience: Outcomes Assessment Among Persons with RRMS who are Receiving Their Care at a Well-Established MS Center and Have used the Immunomodulating Therapies Long-Term, 2002-2004.

  21. Investigator-Initiated: A Survey With Individualized Feedback Regarding Low Bone Mineral Density Among People With MS, 2001-2003.

  22. Investigator-Initiated: A Survey Of Issues Related To Fatigue Among A Large Group Of People With MS, 2001-2003.

  23. Investigator-Initiated: Efficacy, Safety, And Prevalence Of Acupuncture Use Among A Group Of People With MS, 2000-2002.

  24. Investigator-Initiated: Effect of Donepezil on Cognitive Dysfunction in Multiple Sclerosis Patients, 2000-2003.

  25. Teva Pharmaceuticals: PROMISE Trial (safety and efficacy of glatiramer acetate in patients with primary progressive MS), 1999-2002.

  26. Biogen: Intravenous Antegren In Patients With MS During Exacerbation, 1998-1999.

  27. ICOS: Hu23-F2G In MS Patients With Exacerbations, 1998-1999.